PMID- 18461054
OWN - NLM
STAT- MEDLINE
DCOM- 20080804
LR  - 20171116
IS  - 1525-0024 (Electronic)
IS  - 1525-0016 (Linking)
VI  - 16
IP  - 7
DP  - 2008 Jul
TI  - Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin 
      disease by targeting cutaneous dendritic cells.
PG  - 1323-30
LID - 10.1038/mt.2008.91 [doi]
AB  - Induction of the co-stimulatory molecule CD86 on dendritic cells (DCs) in the 
      peripheral tissues is a critical event in triggering antigen-specific immune 
      responses. In this study, we propose a new small interfering RNA (siRNA)-based 
      therapy using cream-emulsified CD86 siRNA, targeting DCs for murine contact 
      hypersensitivity (CH) and atopic dermatitis (AD)-like disease. Topical 
      application of CD86 siRNA efficiently inhibited CH and markedly decreased the 
      numbers of infiltrating CD86(+) or major histocompatibility complex (MHC) class 
      II(+) cells in murine ear skin. The total number of cells, the percentage of 
      hapten-carrying DCs, and their CD86 expression in the regional lymph nodes (RLNs) 
      also significantly decreased. These results suggest that the silencing of CD86 in 
      local DCs inhibits the recruitment and migration of DCs into the skin and RLNs, 
      respectively, resulting in reduced antigen-specific local inflammation. The 
      therapeutic efficacy of the CD86 siRNA was confirmed in AD-prone NC/Nga mice. 
      Treatment produced marked amelioration in the clinical manifestations of AD and 
      reduced the antigen-specific production of interleukin-4 (IL-4) and serum 
      immunoglobulin E (IgE) and IgG1. Our results suggest that the targeting of 
      cutaneous DCs by CD86 siRNA may be a promising strategy in the treatment of 
      allergic skin disease.
FAU - Ritprajak, Patcharee
AU  - Ritprajak P
AD  - Department of Molecular Immunology, Graduate School, Tokyo Medical and Dental 
      University, Bunkyo-ku, Tokyo, Japan.
FAU - Hashiguchi, Masaaki
AU  - Hashiguchi M
FAU - Azuma, Miyuki
AU  - Azuma M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080506
PL  - United States
TA  - Mol Ther
JT  - Molecular therapy : the journal of the American Society of Gene Therapy
JID - 100890581
RN  - 0 (B7-2 Antigen)
RN  - 0 (Emulsions)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (RNA, Small Interfering)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - B7-2 Antigen/*genetics/metabolism
MH  - Base Sequence
MH  - Cell Movement/drug effects
MH  - Dermatitis, Allergic Contact/*drug therapy
MH  - Emulsions
MH  - Female
MH  - Gene Silencing
MH  - Histocompatibility Antigens Class II/analysis
MH  - Immunoglobulin E/blood
MH  - Langerhans Cells/*drug effects/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - RNA, Small Interfering/*administration & dosage
MH  - Skin/*drug effects/metabolism
EDAT- 2008/05/08 09:00
MHDA- 2008/08/05 09:00
CRDT- 2008/05/08 09:00
PHST- 2008/05/08 09:00 [pubmed]
PHST- 2008/08/05 09:00 [medline]
PHST- 2008/05/08 09:00 [entrez]
AID - S1525-0016(16)32474-1 [pii]
AID - 10.1038/mt.2008.91 [doi]
PST - ppublish
SO  - Mol Ther. 2008 Jul;16(7):1323-30. doi: 10.1038/mt.2008.91. Epub 2008 May 6.